Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration

被引:7
|
作者
Jelin, Elma [1 ,2 ]
Wisloff, Torbjorn [3 ,4 ]
Moe, Morten C. [1 ,2 ]
Heiberg, Turid [5 ,6 ]
机构
[1] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Norwegian Inst Publ Hlth, Oslo, Norway
[4] Univ Oslo, Inst Hlth & Soc, Oslo, Norway
[5] Oslo Univ Hosp, Reg Res Support, Oslo, Norway
[6] Ostfold Univ Coll, Halden, Norway
关键词
age-related macular degeneration; anti-VEGF; intravitreal injections; patient perspective; patient-derived questionnaire; patient-reported outcome measures; ANTI-VEGF TREATMENT; EYE; RANIBIZUMAB; EXPERIENCES; IMPACT; RISK;
D O I
10.1111/aos.13847
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose Studies reporting on patient perspectives during treatment of neovascular age-related macular degeneration (nAMD) are limited. Thus, the aim of this study was to develop and test psychometric performance of a patient-derived questionnaire to capture important experiences during intravitreal treatment. Methods Patients (n = 44) with at least 3-month experience of intravitreal injection treatment for nAMD identified the dimensions of priority and also performed a weighting procedure to develop a score for comparison. The questionnaire comprised two versions: one focusing on the relative importance' of the dimensions and one on the experience of the 'management' during treatment. The questionnaire was then tested for psychometric performance in a longitudinal design in newly diagnosed patients at baseline (n = 197), after three (n = 184) and six (n = 150) months of treatment. Results Of the 15 included dimensions, the following were most frequently reported: 'receive treatment to preserve vision', 'information', 'waiting time', 'trust' and 'accommodating staff. The psychometric testing showed moderate reliability (intraclass correlation coefficient: 0.65-0.67) for the two versions and high level of face validity (8.3). The dimensions, 'preserving vision', 'early access to treatment', 'pain relief', 'information about the treatment/diagnosis' and 'visual aids' were consistently reported higher in 'importance' than in 'management', at both 3 and 6 months, indicating a potential for improvement in clinical practice for these dimensions. Conclusion This study provides a brief patient-derived questionnaire, expressed with a score with good psychometric performance that can be used for monitoring during intravitreal injection treatment of nAMD patients.
引用
收藏
页码:804 / 811
页数:8
相关论文
共 50 条
  • [21] Ranibizumab: treatment in patients with neovascular age-related macular degeneration
    Pieramici, Dante J.
    Avery, Robert L.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (11) : 1237 - 1245
  • [22] Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
    Martin, Daniel F.
    Maguire, Maureen G.
    Fine, Stuart L.
    Ying, Gui-shuang
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Redford, Maryann
    Ferris, Frederick L., III
    [J]. OPHTHALMOLOGY, 2012, 119 (07) : 1388 - 1398
  • [23] Combination therapy for the treatment of neovascular age-related macular degeneration
    Englander, Miriam
    Kaiser, Peter K.
    [J]. CURRENT OPINION IN OPHTHALMOLOGY, 2013, 24 (03) : 233 - 238
  • [24] Treatment of neovascular age-related macular degeneration: Current therapies
    Augustin, Albert J.
    Scholl, Stefan
    Kirchhof, Janna
    [J]. CLINICAL OPHTHALMOLOGY, 2009, 3 : 175 - 182
  • [25] VEGF inhibitors for the treatment of neovascular age-related macular degeneration
    Barakat, Mark Rami
    Kaiser, P. K.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (05) : 637 - 646
  • [26] Review of Neovascular Age-Related Macular Degeneration Treatment Options
    Holekamp, Nancy M.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2019, 25 (07): : S172 - S181
  • [27] Pegaptanib sodium for the treatment of neovascular age-related macular degeneration
    Moshfeghi, AA
    Puliafito, CA
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (05) : 671 - 682
  • [28] Personalized Approach in Treatment of Neovascular Age-Related Macular Degeneration
    Kirkova, Radina
    Murgova, Snezhana
    Kirkov, Vidin
    Tanev, Ivan
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (09):
  • [29] Ranibizumab for neovascular age-related macular degeneration
    Rosenfeld, Philip J.
    Brown, David M.
    Heier, Jeffrey S.
    Boyer, David S.
    Kaiser, Peter K.
    Chung, Carol Y.
    Kim, Robert Y.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1419 - 1431
  • [30] Imaging in Neovascular Age-Related Macular Degeneration
    Gess, Adam J.
    Fung, Anne E.
    Rodriguez, Jorge G.
    [J]. SEMINARS IN OPHTHALMOLOGY, 2011, 26 (03) : 225 - 233